

# Bibliography of published COVID-19 in children literature

Philippa Anna Stilwell <sup>1</sup>, Alasdair P. S. Munro,<sup>2,3</sup> Emre Basatemur,<sup>4</sup>  
Nishanthi Talawila Da Camara,<sup>5</sup> Rachel Harwood <sup>6,7</sup> Damian Roland <sup>8,9</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/archdischild-2021-321751>).

For numbered affiliations see end of article.

## Correspondence to

Alasdair P. S. Munro, National Institute of Health Research Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK; A.Munro@soton.ac.uk

PAS and APSM are joint first authors.

Received 30 January 2021  
Revised 14 April 2021  
Accepted 25 April 2021  
Published Online First  
6 May 2021

## ABSTRACT

**Background** The COVID-19 pandemic is the biggest worldwide health challenge in this century. Research concerning the role of children in the spread of SARS-CoV-2, and investigating the clinical effects of infection in children, has been vital. This paper describes the publication trend for pertinent scientific literature relating to COVID-19 in children during the first 6 months of the pandemic.

**Methods** A comprehensive search of preprint and published literature was conducted daily across four databases (PubMed, Scopus, Ovid-Embase and MedRxiv) between 1 January 2020 and 30 June 2020. Titles and abstracts were screened against predefined inclusion and exclusion criteria.

**Findings** Over the study period, a total of 45 453 papers were retrieved, of which 476 met our inclusion criteria. The cumulative number of children described in included publications totalled (at most) 41 396. The median number of children per paper was 6 (IQR 1–33). Nearly one-third of papers (30.2%) reported on a single child, and a further 28.3% reported on between 1 and 9 children. Half of all the publications originated from Asia.

**Interpretation** Our prospective bibliographic analysis of paediatric COVID-19 publications demonstrated a steady increase in the number of papers over time. Understanding and policy evolved with new information that was gathered over the course of the study period. However, over half of publications were individual case reports or small case series, which may have had a limited contribution to advancement of knowledge. During a pandemic, literature should be interpreted with great caution, and clinical/policy decisions should be continually reviewed in light of emerging evidence.

## INTRODUCTION

The COVID-19 pandemic is the biggest worldwide emerging health challenge in this century. This has created a huge need for research, from basic science to all phases of pharmacological studies and qualitative health science evaluation. While COVID-19 disease has been reported in children and young people (CYP) of all ages, including at birth,<sup>1–3</sup> most confirmed cases have been in adults.

Infection with SARS-CoV-2 has taken a milder course in children than in adults: most infected children have presented with mild symptoms or have been asymptomatic.<sup>4–7</sup> However, numerous publications have warned of unintended consequences to children in the form of adverse life events, poor access to education and widening inequality.<sup>8</sup> The balance between the direct and indirect effects of

## What is already known?

- There was an urgent need for rapid dissemination of evidence during the early phases of the COVID-19 pandemic. However, the quality and timing of availability of evidence has not previously been described.

## What this study adds?

- This paper describes the dynamic changes in global volume of literature relating to COVID-19 in children and young people published over the first 6 months of the pandemic. Two-thirds of all papers published described just nine patients or fewer.

the disease on children highlights the challenge of interpreting scientific certainty in complex systems and its impact on national and local public health decision making.

As the COVID-19 pandemic unfolded, the urgency of the need for evidence to inform policy making and practice came to the fore. As a result, an expert COVID-19 literature in children group was brought together, with membership from clinicians, the Royal College of Paediatrics and Child Health (RCPCH) and *Don't Forget the Bubbles* (DFTB) (a not-for-profit educational website).<sup>9</sup> The aim of this was to be able to conduct a daily rapid and dynamic review process, balancing methodological rigour with the need to quickly synthesise and produce clinically useful output for clinicians on the front line.

This paper describes the publication trends of all the pertinent scientific literature relating to COVID-19 in children in the first 6 months of the global pandemic.

## METHODS

### Data sources and search strategy

A comprehensive search of preprint and published literature was conducted daily across four databases between 1 January 2020 and 30 June 2020. After this point, the decision was made to move to weekly searches and a more selective review process due to the volume of publications and the less acute need for rapid dissemination.

The search strategy, developed in PubMed, Scopus, Ovid-Embase and, manually, on MedRxiv,



© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Stilwell PA, Munro APS, Basatemur E, et al. *Arch Dis Child* 2022;**107**:168–172.

consisted of keywords and Medical Subject Headings (MeSH) terms related to COVID-19.<sup>10</sup> Synonyms, alternate spellings, abbreviations and historical terms were incorporated.

### Study types

Observational studies including case reports, case series, cross-sectional studies, intervention studies (including randomised controlled trials) and cohort studies.

### Inclusion and exclusion criteria


Studies that described either epidemiological data, clinical features, vertical transmission, neonatal outcomes, predictors of severity, or prognosis and complications of SARS-CoV-2 in CYP aged between 0 and 18 years old were deemed eligible. Only publications in English were included. Papers where adult and paediatric data were combined, and paediatric data could not be extracted, were excluded. Systematic reviews, other review articles, letters/communications that did not provide clinical data and studies with irredeemable methodological flaws as determined by consensus of at least two clinical academics were excluded.

**Study screening and quality assessment:** all references identified by searches were exported to endnote, and duplicates were removed. One reviewer screened titles and abstracts against the inclusion/exclusion criteria (NTDC). All potentially relevant articles were sent for full text review by one of a panel of 45 independent reviewers, who confirmed that inclusion criteria were met. We were unable to formally assess methodological quality and risk of bias due to feasibility constraints on the large volume of articles and the rapid nature of the review process. Quality and bias were informally, qualitatively assessed by the study reviewers and a clinical academic for written reviews.

**Data extraction:** 45 independent reviewers extracted key data from studies that met the inclusion criteria into a data extraction tool. This captured information about each paper's date of publication (representing either the date of first online publication in a peer-reviewed journal or in some cases the date of publication in a preprint repository), number of children described and country of origin. In addition, each paper was categorised into one of the three main themes: epidemiology (Epi), clinical studies (Clin) and neonatal (Neo). Subsequently, further subcategories were added and applied both prospectively and retrospectively as the evidence base broadened (Epi: disease burden, Epi: transmission, Clin: clinical features, Clin: comorbidities, Clin: paediatric multisystem inflammatory syndrome – temporally associated with SARS-CoV-2 (PIMS-TS) and Clin: therapeutics).

All papers that met the inclusion criteria and deemed potentially relevant were summarised and published on the DFTB website.<sup>9</sup> A narrative synthesis of all the summaries was published on the RCPCH website,<sup>11</sup> updated on a weekly. To quantify the utility of the evidence and review output, data on the respective websites was collected over time, including Altmetric scores (an automatically calculated weighted count of all the attention a research output has received).

Following early concerns of the same patients appearing in multiple reports,<sup>12</sup> all papers originating from China were further assessed for potential duplicate reporting of participants. Data were extracted regarding the institution(s) from which patients were recruited, the start and end dates for recruitment, the age range of included participants and any other limitations to the inclusion criteria (eg, studies limited to children admitted to intensive care). For each publication from China, the number of other papers with overlapping inclusion criteria



**Figure 1** Graph to show number of search hits and included papers, by fortnight, between 01 January 2020 and 28 June 2020 (with stacked bars demonstrating theme/category breakdown of papers). Clin, clinical studies; Epi, epidemiology; PIMS-TS, paediatric multisystem inflammatory syndrome – temporally associated with SARS-CoV-2.

and recruitment site(s) were determined. Papers for which data were missing regarding recruitment site or recruitment period were excluded from this analysis, as were papers reporting data at a regional or national level.

## RESULTS

### Bibliography

Between 1 January 2020 and 30 June 2020, a total of 45 453 papers were retrieved by the search, of which 476 satisfied our inclusion criteria (figure 1 and online supplemental file 1). The median number of search hits per week was 906 (IQR: 211–3345) and peaked at 5178 during the week commencing 18 May. The median number of papers meeting criteria for inclusion per week was 18 (IQR: 3–29). The number of search hits remained stable at around 4000 per week until the end of the study period, whereas the number of included papers declined as time went on, falling to 15 during the last week of June.

Table 1 summarises the distribution of papers included by study size (number of children included), continent and category. The cumulative number of children described in all publications totalled 41 396; however, there is likely to be substantial overlap of patients across publications.

The median number of children per paper was 6 (IQR 1–33). Nearly one-third of papers (30.2%) reported on a single child only, and a further 28.3% reported on between one and nine children (ie, 58% of studies included reported on nine or fewer children). Figure 2 shows the number of children reported on, in included studies, over time. The largest category of publications was classified under the theme ‘clinical features’, with a total of 190 (39.9%) publications, followed by 131 (27.5%) for ‘neonates’.

The number of publications by continent varied widely (table 1), with half of the publications from Asia (50.0%) and just under a third from Europe (29.6%). One hundred and eighty-one publications (38.0%) originated from China. The distribution of publications from different regions broadly followed the path of the pandemic, peaking in Asia first, followed by Europe and subsequently North America (figure 3 and figure 4). PIMS-TS papers peaked in May and June and were published almost exclusively from Europe and North America.


**Table 1** Distribution of papers by study size, paper theme and geographical location

Study size categories (N=470, missing for 6*)	n (%)
1	142 (30.2)
2–9	133 (28.3)
10–49	99 (21.1)
50–99	29 (6.2)
100–999	58 (12.3)
1000–4999	9 (1.9)
Paper theme (n=476)	n (%)
Clinical features	190 (39.9)
Comorbidities	38 (8.0)
PIMS-TS	29 (6.1)
Neonates	131 (27.5)
Therapeutics	3 (0.6)
Epidemiology – transmission	40 (8.4)
Epidemiology – disease burden	45 (9.5)
Continent (n=476)	n (%)
Asia	238 (50.0)
Europe	141 (29.6)
North America	82 (17.2)
South America	5 (1.1)
Australia	4 (0.8)
Africa	2 (0.4)
Multiple continents	4 (0.8)


\*Study size missing for: three studies that included both adults and children and did not provide information about study size separately for children. Three modelling studies that either did not use any direct patient data or did not provide information about size of data source(s) from which the model(s) were extrapolated. PIMS-TS, paediatric multisystem inflammatory syndrome – temporally associated with SARS-CoV-2.

Despite publications peaking in Asia first, only two publications regarding PIMS-TS came from Asia.<sup>13 14</sup>

Of the 181 publications from China, data were available for 142 (78.5%) regarding potential duplicate reporting of participants. Among the 142 studies with data available, 103 (72.5%) were found to have overlapping inclusion criteria and recruitment site(s) with at least one other paper (table 2). The median number of overlapping publications per paper was 2 (IQR 0–5, range 0–26). Among papers reporting data from Hubei Province (n=75), where SARS-CoV-2 was first reported, the median number of overlapping publications per paper was 5 (IQR 2–16). There were 23 studies reporting patients recruited from Wuhan Children’s Hospital.



**Figure 2** Scatter plot demonstrating number of children reported on in included literature, over time.




**Figure 3** Number of publications from each continent by fortnight.

**DISCUSSION**

Our prospective bibliographic analysis of COVID-19 publications relevant to children demonstrated a steady increase in the number of papers meeting the inclusion criteria over time, before peaking in May 2020 and tailing off in June. The rate of publication closely mirrored the trends in numbers of cases during the first phase of the pandemic in the northern hemisphere, following 1 month behind. While the number of included papers fell, the number of search hits continued to increase, reflecting fewer original research articles in proportion to review articles/guidelines/opinion articles.

Critically, the numbers of children included in studies was very small, with one-third of studies reporting on a single child. This is notable given seroprevalence studies have shown up to 4% of children within some of the worst affected European countries may have been infected.<sup>15</sup> This almost certainly reflects under testing of cases of COVID-19 in children due to their milder disease phenotype.<sup>16</sup> While large observational studies require resources and time to deliver, the huge numbers of case studies make a significant proportion of COVID-19 research of limited applicability to clinical practice, due to the inherent bias and unrepresentative nature of n=1 studies.

No interventional studies were reported. There was an extreme paucity of articles regarding therapeutics in children, which were all descriptive in nature and included no clinical trials. Children are commonly excluded from clinical trials of novel therapeutics until they have been conducted in adults,



**Figure 4** World map showing number of included publications by country.

**Table 2** Potential duplicate reporting among Chinese publications (n=142)

Number of overlapping publications per paper	N (%)
0	39 (27.5)
1	28 (19.7)
2–4	34 (23.9)
5–9	16 (11.3)
10–14	5 (3.5)
15–19	9 (6.3)
20–26	11 (7.7)

however given a number of trials such as RECOVERY,<sup>17</sup> were predominantly tested repurposed pharmaceuticals that have a long safety record in children, delays in recruitment of children into high-quality trials only results in random assortments of therapies being given outside of a research context, without the safety provision or oversight of a formal clinical trial. It would be recommended to consider enrolling children in clinical trials earlier and to encourage flexible, rapidly deployable descriptive and interventional studies that can be rolled out using existing research networks and, where possible, generate large and generalisable clinical cohort information.

The importance of research networks and collectives becomes apparent; organisations such as the International Severe Acute Respiratory and Infection Consortium (ISARIC) demonstrated how collaboration can generate generalisable information relatively quickly. ISARIC-4C<sup>18</sup> provided invaluable clinical data at the point of publication, but in the event of future pandemics, consideration should be given to publishing the basic data 'real-time'.

A significant proportion of large studies were prepublished on medRxiv, a preprint server that allows papers to be made available prior to peer-review and publication in journals. This enabled information to be made available rapidly and often preceded journal publication which, during a period of relative data paucity made an impact on information availability.

Geographical spread of publications was uneven but appeared to follow the path of the pandemic. The absence of some clinical phenotypes, such as PIMS-TS, being reported in Asia, even subsequent to cases being described in Europe and North America, remains unexplained and warrants further investigation.

Analysis of papers from China suggested that there was likely to be substantial overlap of patients between some publications. Duplicate reporting falsely inflates the apparent size of the evidence base and has the potential to introduce bias when data across publications is synthesised in systematic reviews and meta-analyses. However, while overlap in inclusion criteria and recruitment site(s) can suggest the potential for duplicate reporting, the true extent of multiple counting cannot be ascertained without individual patient data. This highlights the need for formal, centralised data collection systems.

The prospective nature of this work was only possible due to the generosity of volunteer reviewers. Being able to access continuous, up-to-date information was important for frontline clinicians, who could access summaries directly online but also for policy makers, addressing questions such as when to open schools, which clinical groups to shield and how to manage COVID-19 and PIMS-TS most effectively.

The acute need for rapid, real-time evidence synthesis is reflected in the utilisation statistics for the DFTB and RCPCH web pages, including their use in international policy documents. The DFTB COVID-19 In Children evidence review page<sup>9</sup> went

live in March 2020 and was accessed 128 492 times between then and 30 June 2020. As of 30 June, it had an Altmetric score of 3139, has been cited numerous times in academic publications and referenced in 10 policy documents including from the WHO.<sup>19</sup> The RCPCH research evidence summaries page<sup>11</sup> was accessed 38 094 times between 9 April and 30 June, advised numerous policy outputs and was cited by, for example, UK Research and Innovation.<sup>20</sup>

While the large volumes of research produced provided benefits for sharing information quickly with a wider audience, judicious caution was used when considering the conclusions made by individual papers. We found cross-over publications where data from the same children had been reused.

### Strengths and limitations

To our knowledge, this is the only comprehensive bibliographic overview of all the literature published on COVID-19 in children during the first 6 months of the pandemic. In addition, through the establishment of an expert review network, we were able to identify and formally review a select number of papers that would be most relevant to healthcare professionals working directly with children, organisations supporting clinicians, CYP and their families and policy makers. We have displayed how the research output, globally, evolved over the pandemic.

A decision was made, early in the programme, to exclude data that had not been published in traditional academic literature, due to limitations in formal search strategies and language translation. As a result, when certain organisations or governments published pertinent data that had not been peer reviewed, the data were not included in this report. This is worthy of consideration in the event of future pandemics, as some data were made publicly available by state publications in native languages significantly earlier than when it became available in the formal academic literature,<sup>15</sup> and many countries published relevant documents in native language only. In addition, many national reports were published in PDF format only, impeding web searches. HTML publications would improve accessibility and dissemination of these important data. Systematic reviews and meta-analyses were not included given that the process in place was a rolling systematic review of the literature.

Considering the volume of search hits and limited resource, each paper was only reviewed by one independent reviewer. However, as all written reviews were subsequently screened and edited by clinical academics, we do not believe this to have significantly impacted on the papers sent for review and ultimately included in the evidence summaries that were displayed.

### CONCLUSION

While children have been spared the worst of the clinical impact of COVID-19, evidence regarding features of the disease and its transmission within this population group is essential for healthcare workers, children, families, teachers, as well as local, regional and national policy makers. An expert group was formed between clinicians, RCPCH and DFTB to conduct daily rapid searches of key databases, identifying all published literature relating to CYP and selecting the most pertinent papers to be reviewed, summarised and made available to all, with a significant impact on international policy. Over the first 6 months of the pandemic, 476 papers were identified, describing (at most) 41 396 CYP affected by COVID-19. The number of relevant papers declined as the pandemic progressed, and it is noteworthy that just under one-third of the papers reported on a single child.

**Author affiliations**

<sup>1</sup>Department of Community Paediatrics, Evelina London Children's Hospital, London, UK

<sup>2</sup>NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

<sup>3</sup>Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, Hampshire, UK

<sup>4</sup>UCL Great Ormond Street Institute of Child Health Population Policy and Practice, London, UK

<sup>5</sup>Research and Quality Improvement, RCPCH, London, UK

<sup>6</sup>Department of Paediatric Surgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK

<sup>7</sup>Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK

<sup>8</sup>Department of Health Sciences, University of Leicester, Leicester, UK

<sup>9</sup>Paediatric Emergency Medicine Leicester Academic (PEMLA) Group, University Hospitals of Leicester NHS Trust, Leicester, UK

**Twitter** Rachel Harwood @RachelHarwood10 and Damian Roland @damian\_roland

**Acknowledgements** All the reviewers who contributed to the review process: Alison Boast, Grace Leo, Dani Hall, Dan Yeoh, Melody Redman, Sarah Sloan, Tricia Barlow, Anne Bean, Maeve Kelleher, Victoria Dachtler, Irnthu Premadeva, Daniel Hawcutt, Lilian Nyirongo, Esther Alderson, Tessa Davis, Sunil Bhopal, Aimee Donald, Sarah Blackstock, Alice Armitage, Anne-Lise Goddings, Lyda Jadresic, Maham Zaman, Celia Avigdor, David Beverley, Hilary Smith, Vivienne van Someren, Brendan Harrington, Louise Tina Day, Sarah Hall, Alastair Falconer, Sarah Lee, Noel Murphy, Chris Lamming, Carlos de Sousa, Mike Hall, Nandhini Prakash, Maggie Fitzpatrick, Robert Scott Jupp, Bhupinder Sandhu, Rob Primhak and Richard Morton. The Children and Young People's Transformation Team at National Health Service (NHS) England and NHS Improvement. The Research and Evidence Team at the Royal College of Paediatrics and Child Health for managing the literature searches and the Senior Officers for their advice and feedback. Tessa Davis from Don't Forget the Bubbles for support with data analysis.

**Contributors** PAS contributed to the conception and design, interpretation of data, drafted the initial draft, revised the draft and approved the final version to be published. AM contributed to the conception and design, acquisition and interpretation of data, revised the draft and approved the final version to be published. PAS and AM contributed equally as joint first authors. EB contributed to the design, analyses/interpretation of data, revised the draft and approved of the final version to be published. NTDC contributed to the conception and design, acquisition and analyses of data, revised the draft and approved of the final version to be published. RH contributed to the design, revised the draft and approved of the final version to be published. DR contributed to the conception and design, interpretation of data, revised the draft and approved of the final version to be published.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Map disclaimer** The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. Data available on request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,

terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**ORCID iDs**

Philippa Anna Stilwell <http://orcid.org/0000-0002-9178-8985>

Rachel Harwood <http://orcid.org/0000-0003-3440-3142>

Damian Roland <http://orcid.org/0000-0001-9334-5144>

**REFERENCES**

- 1 Qiu H, Wu J, Hong L, *et al*. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis* 2020;20:689–96.
- 2 Yu N, Li W, Kang Q, *et al*. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet Infect Dis* 2020;20:559–64.
- 3 Zeng L, Xia S, Yuan W, *et al*. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA Pediatr* 2020;174:722–5.
- 4 World Health Organisation. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19), 2020. Available: [www.who.int/docs/default-source/coronavirus/who-china-joint-mission-on-covid-19-final-report.pdf](http://www.who.int/docs/default-source/coronavirus/who-china-joint-mission-on-covid-19-final-report.pdf) [Accessed 8 Jan 2021].
- 5 Bi Q, Wu Y, Mei S. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. *Lancet Infectious Diseases* 2020;20:911–9.
- 6 Bellino S, Punzo O, Rota MC, *et al*. COVID-19 disease severity risk factors for pediatric patients in Italy. *Pediatrics* 2020;146:e202009399.
- 7 Davies NG, Klepac P, Liu Y. CMMID COVID-19 Working Group. age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med* 2020;26:1205–11.
- 8 Crawley E, Loades M, Feder G, *et al*. Wider collateral damage to children in the UK because of the social distancing measures designed to reduce the impact of COVID-19 in adults. *BMJ Paediatr Open* 2020;4:e000701.
- 9 Boast A, Munro A, Goldstein H. An evidence summary of paediatric Covid-19 literature. Available: <https://dontforgetthebubbles.com/evidence-summary-paediatric-covid-19-literature/> [Accessed 9 Dec 2020].
- 10 Covid-19 search protocol and inclusion criteria. Available: [https://www.rcpch.ac.uk/sites/default/files/2020-05/rcpch\\_covid-19\\_search\\_strategy.pdf](https://www.rcpch.ac.uk/sites/default/files/2020-05/rcpch_covid-19_search_strategy.pdf) [Accessed 9 Dec 2020].
- 11 Covid-19 – research evidence summaries, 2020. Available: <https://www.rcpch.ac.uk/resources/covid-19-research-evidence-summaries> [Accessed 9 Dec 2020].
- 12 Bauchner H, Golub RM, Zylke J. Editorial Concern-Possible reporting of the same patients with COVID-19 in different reports. *JAMA* 2020;323:1256.
- 13 Balasubramanian S, Nagendran TM, Ramachandran B, *et al*. Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. *Indian Pediatr* 2020;57:681–3.
- 14 Schnapp A, Abulhija H, Maly A, *et al*. Introductory histopathological findings may shed light on COVID-19 paediatric hyperinflammatory shock syndrome. *J Eur Acad Dermatol Venereol* 2020;34:e665–7.
- 15 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, *et al*. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* 2020;396:535–44.
- 16 Waterfield T, Watson C, Moore R, *et al*. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. *Arch Dis Child* 2021;106:680–6.
- 17 Recovery: randomised evaluation of Covid-19 therapy. Available: <https://www.recoverytrial.net/> [Accessed 5th Jan 2020].
- 18 Docherty Annemarie B, Harrison Ewen M, Green Christopher A. Features of 20,133 UK patients in hospital with Covid-19 using the ISARIC who clinical characterisation protocol: prospective observational cohort study. *BMJ* 1985;2020:369.
- 19 World Health Organisation (WHO). Considerations for school-related public health measures in the context of Covid-19. Available: <https://www.who.int/publications-detail/considerations-for-school-related-public-health-measures-in-the-context-of-covid-19> [Accessed 9 Dec 2020].
- 20 UK Research and Innovation (UKRI).. Coronavirus in children: are children immune from COVID-19? Available: <https://coronavirusexplained.ukri.org/en/article/und0008/> [Accessed 9 Dec 2020].